Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Rises By 32.4%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 200,000 shares, a growth of 32.4% from the August 15th total of 151,100 shares. Based on an average daily trading volume, of 72,500 shares, the short-interest ratio is currently 2.8 days. Currently, 1.2% of the shares of the company are sold short.

Hedge Funds Weigh In On Cyclo Therapeutics

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Founders Fund V Management LLC acquired a new position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics makes up 80.8% of Founders Fund V Management LLC’s holdings, making the stock its biggest holding. Founders Fund V Management LLC owned about 2.11% of Cyclo Therapeutics at the end of the most recent reporting period. 68.55% of the stock is owned by hedge funds and other institutional investors.

Cyclo Therapeutics Price Performance

Shares of NASDAQ CYTH remained flat at $0.64 during trading on Monday. 20,663 shares of the stock traded hands, compared to its average volume of 78,459. Cyclo Therapeutics has a 1-year low of $0.59 and a 1-year high of $2.12. The firm’s fifty day simple moving average is $1.03 and its two-hundred day simple moving average is $1.25. The firm has a market capitalization of $18.37 million, a price-to-earnings ratio of -0.64 and a beta of -0.38.

Cyclo Therapeutics (NASDAQ:CYTH) last released its earnings results on Thursday, August 15th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.07). Cyclo Therapeutics had a negative net margin of 1,830.27% and a negative return on equity of 2,741.89%. The firm had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.40 million. Sell-side analysts predict that Cyclo Therapeutics will post -0.66 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Maxim Group reaffirmed a “hold” rating on shares of Cyclo Therapeutics in a research note on Tuesday, August 27th. HC Wainwright reaffirmed a “neutral” rating and issued a $0.95 price objective (down previously from $3.00) on shares of Cyclo Therapeutics in a report on Friday, August 23rd. Finally, Ascendiant Capital Markets lowered their target price on shares of Cyclo Therapeutics from $2.60 to $0.95 and set a “buy” rating on the stock in a research note on Monday, August 26th.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.